Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

NBCS Collaborators, ABCTB Investigators

Research output: Contribution to journalArticle

Abstract

In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. Since HOXB13 p.G84E is a prostate cancer risk allele, we evaluated the association between HOXB13 germline mutations and breast cancer risk in a previous study consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherlands. Although both recurrent HOXB13 mutations p.G84E and p.R217C were not associated with breast cancer risk, the risk estimation for p.R217C was not very precise. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR = 1.035, 95% CI = 0.859-1.246, P = 0.718 and OR = 0.798, 95% CI = 0.482-1.322, P = 0.381 respectively), nor in specific high-risk subgroups or breast cancer subtypes. Thus, although involved in breast cancer progression, HOXB13 is not a material breast cancer susceptibility gene.

Original languageEnglish (US)
Pages (from-to)9688
Number of pages1
JournalScientific reports
Volume10
Issue number1
DOIs
StatePublished - Jun 16 2020

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk'. Together they form a unique fingerprint.

  • Cite this